LBA33 - Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial

The TLR9 agonist lefitolimod broadly activates the innate and adaptive immune system. Based on encouraging data from the randomized phase II IMPACT trial, lefitolimod was evaluated in this phase III trial as switch maintenance treatment in patients with mCRC who have responded to first-line therapy....

Full description

Bibliographic Details

Published in:	Annals of oncology Vol. 30; pp. v868 - v869
Main Authors:	Cunningham, D., Salazar, R., Sobrero, A., Ducreux, M.P., Van Cutsem, E., Scheithauer, W., Tournigand, C., Molnar, V., Starke, M., Baumann, M., Wiegert, E., Schmidt, M., Arnold, D.
Format:	Journal Article
Language:	English
Published:	Elsevier Ltd 01-10-2019
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!